In 1991, Kruger et al. demonstrated expression of CD73 in breast carcinoma[16] and a further 19 years of target biology exploration and experimental validation ensued before Stagg et al. demonstrated that an anti-CD73 antibody could inhibit breast tumour growth and metastasis[17]. The gene discussed is NT5E; the disease is breast carcinoma.